Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
$70.69
$0.53(0.67%)
At close: 4:00 PM EST
$70.69
$0.53(0.67%)
Day’s Range― - ―
52-Week Range$54.11 - $89.98
Previous CloseN/A
Volume488.69K
Average Volume (3M)5.05M
Market Cap
$27.21B
Enterprise Value$27.03B
Total Cash (Recent Filing)$2.00B
Total Debt (Recent Filing)$1.39B
Price to Earnings (P/E)31.0
Beta1.09
Next Earnings
Apr 23, 2026EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding384,864,840
10 Day Avg. Volume3,778,931
30 Day Avg. Volume5,050,871
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)9.43
Price to Sales (P/S)5.56
P/FCF Ratio24.04
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue5.80
Enterprise Value/Gross Profit9.65
Enterprise Value/Ebitda20.22
Forecast
1Y Price Target
$86.94Price Target Upside22.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)2.49
Revenue Forecast (FY)$5.23B
Bulls Say, Bears Say
Bulls Say
International Expansion And Software PlatformStronger international revenue growth combined with rollout of the Stelo app platform could accelerate global adoption and allow overseas sales to outpace domestic markets, supporting long‑term revenue upside.
Medicare Coverage ExpansionPotential expansion of Medicare coverage to include non-insulin type 2 diabetes patients could materially increase the addressable market and drive significant volume growth as clinical data and registries demonstrate benefit.
Sensor Adoption And ProfitabilityWider adoption of the G7 and longer‑wear 15‑day sensor is lifting patient demand and manufacturing efficiency, which could improve profit margins and raise revenue per user as conversions increase.
Bears Say
Guidance Shortfall Versus ExpectationsManagement's revenue outlook running below the firm's internal forecast raises the risk that reported growth may trail analyst projections and temper upside to the stock.
Margin PressureReported gross margins and management outlook indicate profit margins may be lower than some analyst forecasts, creating downside risk to earnings if cost or pricing pressures persist.
Operational And Reliability RisksA ramp of a new manufacturing facility together with recent reliability concerns could disrupt operations, reduce confidence among patients and providers, and weigh on near‑term results.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $54.11 and its highest was $89.98 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $27.21B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Apr 23, 2026 which is in 47 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Feb 12, 2026. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.47.
How many shares outstanding does Dexcom have?
Dexcom has 384,864,840 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.68 in its last earnings report, beating expectations of $0.65. Following the earnings report the stock price went up 7.591%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.94 (22.99% Upside)
$86.94 (22.99% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.75%
12-Months-Change
Fundamentals
Return on Equity
34.50%
Trailing 12-Months
Asset Growth
-2.23%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Company Deck
DXCM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational recovery, solid revenue and margin improvement, robust cash generation, and several product and commercialization catalysts (G7 15-day, Smart Basal, Stelo, EHR integration). Management acknowledged prior supply/sensor deployment issues but demonstrated clear remediation and sequential margin recovery. Near-term headwinds include ramp-related OpEx for the Ireland facility, Q1 cadence seasonality, and uncertainty around CMS timing and competitive/payer dynamics, but these are framed as manageable or temporary. Overall the positives (growth, margin expansion, cash, product momentum) materially outweigh the headwinds.View all DXCM earnings summariesDXCM Revenue Breakdown
71.53% U.S.
28.47% International
DXCM Stock 12 Month Forecast
Average Price Target
$86.94
▲(22.99% Upside)
Technical Analysis
Ownership Overview
0.48% Insiders
24.69% Mutual Funds
13.54% Other Institutional Investors
28.63% Public Companies and Individual Investors